Back in 2014, within a discussion with Ribas regarding ASCO 2014 reports, Weber said this: "....Injectable therapies are making a comeback.....eons ago we were injecting BCG, interferon, and IL-2 into local-regional melanoma metastasis.....now there are some interesting drugs, and T-VEC is one of them. I see this as a niche drug that would be best used to prime the immune system and follow up with a drug such as pembrolizumab, nivolumab, ipi, or a combination of those....that's where I see intralesional therapy going."
I have put together many posts regarding T-VEC....this one recently: T-VEC: more good news...local and systemic responses
OR....here's what I noted before in a post about the intralesional therapy OncoVEX:
"OncoVEX is a 2nd generation herpes virus embedded with GM-CSF...a substance that causes the body to make more white cells. (GM-CSF can be given to premature babies and leukemia patients with low white cell counts to help build them back up....and reverse immune suppression.) But, in OncoVEX, it is thought to only replicate in the tumor cells. The white cells produced in the process kill off the tumor cells. In a phase 2 trial reported in 2012, 20% of patients achieved a complete response and 28% gained an overall response. 92% of the responses were durable to at least 6 months, and the majority were ongoing with a range of 18-40 months. Responses were found in patients with all stages and systemic tumors were eradicated in some patients."